# Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

> **NCT04482712** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Respiratory Failure
- Sars-CoV2

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04482712
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04
- **Primary completion:** 2022-01
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was never submitted to IRB or approved, due to feasibility issues
- **Last updated:** 2021-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04482712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04482712, "Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04482712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*